Discover the new Chem-Impex: Where innovation starts with a bond.

Catalog Number:
42187
CAS Number:
356559-20-1
SB-525334
Purity:
≥ 98% (HPLC)
Synonym(s):
6-[2-(tert-Butyl)-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl]quinoxaline
Hazmat
Documents
$221.63 /10MG
Pack Size Availability Price
Request Bulk Quote
Product Information
Synonyms
6-[2-(tert-Butyl)-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl]quinoxaline
CAS Number
356559-20-1
Purity
≥ 98% (HPLC)
Molecular Formula
C21H21N5
Molecular Weight
0
MDL Number
MFCD11045307
PubChem ID
9967941
Melting Point
156 - 160 °C
Appearance
White, yellow or orange powder or crystals
Conditions
Store at 2 - 8 °C
General Information
Synonyms
6-[2-(tert-Butyl)-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl]quinoxaline
CAS Number
356559-20-1
Purity
≥ 98% (HPLC)
Molecular Formula
C21H21N5
Molecular Weight
0
MDL Number
MFCD11045307
PubChem ID
9967941
Melting Point
156 - 160 °C
Appearance
White, yellow or orange powder or crystals
Conditions
Store at 2 - 8 °C
Properties
Additional property information coming soon!
-
Safety and Regulations
Hazmat
Yes
Antibiotic
No
DEA-regulated
No
Warnings
-
Applications

SB-525334 is widely utilized in research focused on:

  • Oncology Research: This compound is being explored for its potential as an anti-cancer agent, particularly in targeting specific pathways involved in tumor growth and survival.
  • Neuroscience Studies: Researchers are investigating its effects on neurodegenerative diseases, aiming to understand how it might protect neuronal cells from damage.
  • Pharmacological Development: SB-525334 serves as a valuable tool in drug discovery, helping scientists to develop new therapeutic strategies for various diseases by modifying its structure for enhanced efficacy.
  • Biochemical Assays: It is used in assays to study enzyme activity and receptor interactions, providing insights into cellular mechanisms and potential drug targets.
  • Combination Therapies: The compound is being evaluated in combination with other drugs to enhance therapeutic outcomes, particularly in resistant cancer types, offering a promising avenue for improving patient care.

Citations